Drug safety comments
This article was originally published in The Tan Sheet
Executive Summary
FDA seeks comments on its draft drug safety five-year plan, according to a notice scheduled for publication in the May 5 Federal Register. The plan, released April 1, outlines how FDA will spend Prescription Drug User Fees, such as on hiring more safety inspectors for marketed medications and more staff to review mandatory post-approval studies, label changes and other risks (1"The Tan Sheet" April 14, 2008, p. 10). Comments are due in June...
You may also be interested in...
FDA’s 5-Year Plan For User Fees Gives Equal Footing To Post- And Pre-Market
Over the next five years, FDA will shift its regulatory focus to ensure that the safe and effective use of drugs is of equal importance as ushering safe and effective medicines to market
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.